Clinical Cardiology Alert – March 1, 2013
March 1, 2013
View Issues
-
Quality of Life in Atrial Fibrillation
The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial randomized 1376 patients with AF and CHF to rhythm- or rate-control treatment strategies. -
Renal Disease and Stroke Risk in Atrial Fibrillation
This study examines the influence of renal dysfunction on stroke risks in two atrial fibrillation (AF) study groups. The ROCKET AF trial was a trial comparing fixed-dose rivaroxaban, a direct factor Xa inhibitor, with adjusted-dose warfarin for prevention of thromboembolic events. -
Best Single Drug for Rate Control of Atrial Fibrillation
Beta-blockers are widely considered first-line therapy for heart rate control in patients with permanent atrial fibrillation (AF), but few comparative effectiveness data with other drugs are available. -
GRACE Score for Diagnosis of Acute Coronary Syndrome
The accurate and timely recognition of acute coronary syndromes (ACS) may facilitate the deployment of evidence-based therapies that could impact outcomes. -
Completeness of Revascularization Matters
During coronary artery bypass graft (CABG) surgery, the aim is to achieve complete revascularization of all the coronary arteries. -
Diagnostic Use of Rapid Volume Infusion
Volume infusion during right heart catheterization has been recommended to distinguish patients with pulmonary hypertension (PH) from those with heart failure with preserved ejection fraction (HFpEF). -
Outcomes with Isolated Right Bundle Branch Block
The appearance of right bundle branch block (RBBB) and incomplete RBBB (IRBBB) in otherwise healthy individuals is believed to be benign, but several cardiac and pulmonary diseases are known to be associated with RBBB and IRBBB. -
Pharmacology Watch: Aspirin Use and Age-Related Macular Degeneration
Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions. -
Clinical Briefs in Primary Care Supplement